Børsnoterte franske MedinCell fikk nå 30 mill i finansiering for å utvikle en Ivermectin basert Covid19 medisin

[John Galt]

Etter over et år med studier og en omfattende sikkerhetsanallyse av Ivermectin, har MedinCell biotech nå fått på plass 3,2 mill USD i finansiering for utvikling av en forebyggende og tidlig behandlings, Ivermectin basert medisin mot Covid19, i tillegg til kliniske studier.

(I tilegg til utviklingen av en ny Ivermectin basert medisin mot Malaria, som fremdeles tar livet av en halv million barn årlig.)

https://www.medincell.com

Sikkerhetsananlyse: 

https://www.medincell.com/ivermectin/

https://www.bloomberg.com/press-releases/2021-04-19/clinical-trial-conducted-by-medincell-confirms-the-safety-of-continuous-administration-of-ivermectin-knorrnr1

https://www.businesswire.com/news/home/20210419005658/en/Clinical-Trial-Conducted-by-MedinCell-Confirms-the-Safety-of-Continuous-Administration-of-Ivermectin

01 Sep 2021 A long-acting single three month injectable ivermectin, is being developed by MedinCell for the treatment of malaria and COVID-2019 infections. MedinCell files Clinical Trial Applications in France and other European countries for COVID-2019 infections

Godkjenning for kliniske studier i UK:

https://www.gov.uk/government/publications/freedom-of-information-responses-from-the-mhra-week-commencing-24-may-2021/freedom-of-information-request-on-the-trial-of-ivermectin-and-the-approval-of-the-clinical-trial-in-healthy-volunteers-foi-21470 

Støttet av Bill & Melinda Gates foundation:

https://www.gatesfoundation.org/about/committed-grants/2021/08/inv030635

Noe av grunnlaget for MedinCell sin Ivermectin beslutning finner du her:

https://ivmmeta.com

 

 

 

 

 

 

 

Endret 5. desember 2021 av John Galt

[Tussa84]

Så flott at de kan lage en annen variant av et legemiddel som allerede eksisterer. Dette kommer godt med, sammen med alle vaksinene mot ulike varianter fremover.

[Jajajane]

Ivermectin 2 😅 

[John Galt]

Vestlig presse har av uforståelige grunner, helt siden starten av pandemien, hatt en sterk negativ bias mot Ivermectin. Et særdeles bredspektret antiparasittisk legemiddel som har vært utskrevet i minst 4 milliarder doser til mennesker de siste 35 årene. Usedvanlig virkningsfullt, nesten gratis, og tilnærmet ingen kjente bivirkninger. Både helbredende og forebyggende virkninger mot en lang rekke sykdommer, uten at man helt forstår hvordan og hvorfor.

Jeg fattet interesse for dette temaet etter at jeg leste dette i April 2020:

The Peter Doherty Institute of Infection and Immunity showed that Ivermectin reduced COVID-19 viral RNA present in cell culture by as much as 93 percent after 24 hours and by 99.8 percent after 48 hours, at around a 5,000-fold reduction in coronavirus RNA, hinting that the medicine can potentially eradicate the virus. It has also shown effectiveness in vitro against a wide range of other viruses, such as the influenza virus, Zika virus, and the human immunodeficiency virus (HIV). Dr. Wagstaff made a previous breakthrough finding on Ivermectin in 2012 when she identified the drug and its antiviral activity with Monash Biomedicine Discovery Institute's Professor David Jans, also an author on this paper. Professor Jans and his team have been researching Ivermectin for more than 10 years with different viruses.

https://www.news-medical.net/news/20200403/Australian-scientists-identify-possible-coronavirus-drug.aspx

Samtidig fanget dette også interessen til MedinCell:

14th April 2020

MEDINCELL INVESTIGATING ROLE OF LONG-ACTING ANTIVIRALS TO BREAK CHAIN OF SARS-COV-2 VIRAL TRANSMISSION 

COVID-19 NEWS

With evidence from Monash University (Melbourne, Australia) indicating that established antiparasitic drug ivermectin can kill coronavirus in a laboratory setting in under 48 hours (a single treatment is able to effect ∼5000-fold reduction in virus at 48h in cell culture1) MedinCell has published data showing that long-acting formulations of ivermectin can be designed with varying doses and durations using its BEPO® technology.2

With a three-month BEPO injectable product to fight malaria 3 already in development, the company believes BEPO could have a role to play in COVID-19 treatment with ivermectin.

The company said that clinical studies were required to confirm the effectiveness of a long-acting injectable formulations in breaking the chain of viral transmission.

PRESS RELEASE

First in vitro validation of impact of Ivermectin on Covid-19 by Australian researchers

• Researchers at Monash University in Melbourne, Australia, have published last Friday a study showing that antiparasitic drug Ivermectin can kill coronavirus in a laboratory setting in under 48 hours. A single treatment is able to effect ∼5000-fold reduction in virus at 48h in cell culture1.
• Ivermectin has a long track record of use as a safe and effective drug to treat several parasitic diseases.
• MedinCell has published data showing that long-acting formulations of Ivermectin can be designed with varying doses and durations with its BEPO® technology2 and is already leading a program aiming at developing a 3-Month injectable product to fight malaria3.
• MedinCell has launched a few weeks ago a research initiative on a long-acting injectable formulation of Ivermectin and believes it could have a role to play in Covid-19 management.
• Future clinical studies will have to confirm the action of Ivermectin on Covid-19 virus, and the potential effectiveness of a long-acting injectable on its prevention and therefore breaking the chain of transmission.
• In case of positive results, a BEPO® technology 1 based long-acting injectable Ivermectin offers a rapidly deployable and affordable solution for a global pandemic.

1. The FDA-approved Drug Ivermectin inhibits the replication of SARS-CoV-2 in vitro – Leon Caly, Julian D. Druce, Mike G. Catton, David A. Jans, Kylie M. Wagstaff – Antiviral Research, 3 April 2020
   Source: BEPO®: Bioresorbable diblock mPEG-PDLLA and triblock PDLLA-PEG-PDLLA based in situ forming depots with flexible drug delivery kinetics modulation – Christophe Roberge, Jean-Manuel Cros, 
2. Juliette Serindoux, Marie-Emérentienne Cagnon, Rémi Samuel, Tjasa Vrlinic, Pierre Berto, Anthony Rech, Joël Richard, Adolfo Lopez-Noriega – Journal of Controlled Release, Volume 319, 10 March 2020, Pages 416-427
3. Company press release: MedinCell receives $ 6.4 million grant from Unitaid to fight Malaria – 03.25.2020

 

 

 

 

 

 

[Elaine Marley]

Tråden er ryddet for spekulasjoner. Elaine Marley, mod.